Davide Capodanno Shares FITTER Trial: Evolocumab Shows No Added Short-Term Benefit in Acute Coronary Syndrome
Davide Capodanno, professor of Cardiology at University of Catania, editor-in-Chief of EuroIntervention, posted on X:
”In the double-blind, randomized FITTER trial, 150 patients with acute coronary syndrome and relevant non-culprit lesions received evolocumab or placebo for 12 weeks in addition to high-intensity statin therapy.
PCSK9 inhibition did not produce additional short-term improvements in plaque lipid content, plaque volume, or coronary physiology.”
Read the full article here.
Find the editorial here.
Article: Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial
Authors: Frans B. Mensink, Jonathan Los, Mohamed M. Reda Morsy, Rohit M. Oemrawsingh, Clemens von Birgelen, Alexander J.J. Ijsselmuiden, Martijn Meuwissen, Jin M. Cheng, Diederik F. van Wijk, Pieter C. Smits, Valeria Paradies, Dirk J. van Wijk, Himanshu Rai, Tim J.F. ten Cate, Cyril Camaro, Peter Damman, Lokien X. van Nunen1, Aukelien C. Dimitriu-Leen, Marleen H. van Wely, Aysun Cetinyurek-Yavuz, Robert A. Byrne, Niels van Royen, Robert-Jan M. van Geuns

Stay informed on all science in Hematology with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team
